VP-20621 is under clinical development by Destiny Pharma and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VP-20621’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VP-20621 is under development for the prevention of Clostridium difficile associated diarrhea (CDAD). The drug candidate is administered through oral route. VP-20621 is a formulation of spores of a non-toxigenic single strain of Clostridium difficile. The drug candidate is based on non-toxigenic spore-based technology.
Destiny Pharma overview
Destiny Pharma, formerly Destiny Pharma, is a drug development and discovery company. It offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to address multi drug resistant microbial pathogens that cause infections. Its pipeline products includes NTCD-M3, XF-73 and SPOR-COV. Destiny Pharma’s products find applications for the treatment of clostridioides difficile infections, post surgical infections, dermal infections and COVID-19. The company has its operations through a network of industries, governments and academia. Destiny is headquartered in Brighton, East Sussex, the UK.
For a complete picture of VP-20621’s drug-specific PTSR and LoA scores, buy the report here.